Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro.
about
A single pulse of agrin triggers a pathway that acts to cluster acetylcholine receptorsMechanisms of resistance in castration-resistant prostate cancer (CRPC)SRC: marker or actor in prostate cancer aggressivenessThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceSrc-dependent Tks5 phosphorylation regulates invadopodia-associated invasion in prostate cancer cellsCancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.Multifocal angiostatic therapy: an update.Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasisSrc protein tyrosine kinase family and acute inflammatory responses.CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness.Nonreceptor tyrosine kinases in prostate cancer.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.Non-Genomic Actions of the Androgen Receptor in Prostate CancerSrc kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.Targeting tyrosine kinases and autophagy in prostate cancer.Steps in prostate cancer progression that lead to bone metastasisAn mRNA-specific tRNAi carrier eIF2A plays a pivotal role in cell proliferation under stress conditions: stress-resistant translation of c-Src mRNA is mediated by eIF2A.Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate canceralpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling.The role of SRC family kinases in prostate cancer.Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].Thioxopyrimidine in Heterocyclic Synthesis III: Synthesis and Properties of Some Novel Heterocyclic Chalcone Derivatives Containing a Thieno[2,3-d]pyrimidine-Based Chromophore
P2860
Q24302188-C2CB7491-4E30-428C-807D-31AA826D74ADQ26774221-CF652ACA-F3A9-4F5F-98F7-F42A3A8E3C84Q27012541-D9FDDB50-7E5B-4C1C-8D6C-98B8F0A239BAQ28076745-EE816437-EA5D-4BBC-8A37-B4A9D1FC0CD1Q33851800-D9FA88C5-FED7-402A-952C-69C825A52B91Q35609713-52A38C26-9675-4EE2-8A3C-93818B389BADQ36087899-0BBA8332-E54D-4BE4-94F0-7B53D26BF6D0Q36311166-E5E33B08-9825-404C-A69D-54482B251C59Q36322698-30133ED8-5B14-402F-BE05-27961EA09FE2Q36438267-602EDE3F-DDDA-4B8B-ACDC-F7A88A258865Q36695688-6DC05200-7B27-429C-956D-EA1FC2754744Q36759212-EFC93DD3-A04B-44E0-8093-34169CC00363Q37092020-3D788783-9C96-4FF5-9008-F1A3C05B1B46Q37502039-BF570B19-5DF4-4781-BCAF-B8B6687A00FAQ37588620-469ABBCF-91BA-4947-849C-896C32E27E6CQ37724378-C56DD590-85D5-4A84-8089-704B46247420Q37847052-071AF421-A888-4A10-92DD-279EB5A814E8Q37848782-7C9D7E1F-148A-4D6F-ADE6-47139ED762B1Q38728366-CDE6D109-2EAB-41C2-B1BC-9684629223C6Q38996065-3C833C04-BA42-488A-A540-555A9DB34A5FQ39970491-F5C941BB-6873-43EB-8949-86A035D22FB4Q40055337-45064F4B-F89C-408E-BAA8-E2D0118F67D9Q40165268-712F62BE-D4C2-4B4B-8BA1-3B733DC85452Q54485558-F2D08F37-A23D-4EE1-B275-D67765C226D3Q54621239-6B411494-D482-468A-98FE-62743AE664AEQ59010152-60113D01-F7E7-46A9-A7E0-78C637140A91
P2860
Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Pyrrolopyrimidine c-Src inhibi ...... rostate cancer cells in vitro.
@en
Pyrrolopyrimidine c-Src inhibi ...... rostate cancer cells in vitro.
@nl
type
label
Pyrrolopyrimidine c-Src inhibi ...... rostate cancer cells in vitro.
@en
Pyrrolopyrimidine c-Src inhibi ...... rostate cancer cells in vitro.
@nl
prefLabel
Pyrrolopyrimidine c-Src inhibi ...... rostate cancer cells in vitro.
@en
Pyrrolopyrimidine c-Src inhibi ...... rostate cancer cells in vitro.
@nl
P2093
P50
P1476
Pyrrolopyrimidine c-Src inhibi ...... prostate cancer cells in vitro
@en
P2093
P304
P356
10.1016/S0959-8049(03)00394-0
P577
2003-09-01T00:00:00Z